These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21565521)

  • 1. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
    Freyer G; Campone M; Peron J; Facchini T; Terret C; Berdah JF; Jacquin JP; Coeffic D; Hilaire Pde S; Falandry C
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):466-73. PubMed ID: 21565521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
    Eckhoff L; Nielsen M; Moeller S; Knoop A
    Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.
    Brain EG; Mertens C; Girre V; Rousseau F; Blot E; Abadie S; Uwer L; Bourbouloux E; Van Praagh-Doreau I; Mourey L; Kirscher S; Laguerre B; Fourme E; Luneau S; Genève J; Debled M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):160-70. PubMed ID: 21035352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
    Takabatake D; Taira N; Hara F; Sien T; Kiyoto S; Takashima S; Aogi K; Ohsumi S; Doihara H; Takashima S
    Jpn J Clin Oncol; 2009 Aug; 39(8):478-83. PubMed ID: 19491086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
    Jones S; Holmes FA; O'Shaughnessy J; Blum JL; Vukelja SJ; McIntyre KJ; Pippen JE; Bordelon JH; Kirby RL; Sandbach J; Hyman WJ; Richards DA; Mennel RG; Boehm KA; Meyer WG; Asmar L; Mackey D; Riedel S; Muss H; Savin MA
    J Clin Oncol; 2009 Mar; 27(8):1177-83. PubMed ID: 19204201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant docetaxel for node-positive breast cancer.
    Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
    N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
    Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
    Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
    Naito K; Oura S; Yoshimasu T; Nakamura R; Hirai Y; Kiyoi M; Miyasaka M; Okamura Y
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1913-6. PubMed ID: 20948255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
    Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
    J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
    Hatam N; Ahmadloo N; Ahmad Kia Daliri A; Bastani P; Askarian M
    Arch Gynecol Obstet; 2011 Jul; 284(1):215-20. PubMed ID: 20740365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
    Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
    Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients.
    Garg P; Rana F; Gupta R; Buzaianu EM; Guthrie TH
    Breast J; 2009; 15(4):404-8. PubMed ID: 19508671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.